Inventa Trials

Renewed Hope. For 25 years, Fort Wayne Medical Oncology and Hematology has been participating in clinical trials, giving patients renewed hope. We opened the Inventa Center for Cancer Research in order to continue our tradition of leading advanced research and clinical trials. Together, we’re working toward breakthroughs in cancer treatment through partnerships with top academic research programs across the country. However, as our patient, you don’t have to travel to take advantage of these opportunities. You can receive these cutting-edge treatment options here at home.


While not everyone is a candidate for clinical trials, there are many trials available to those who qualify. Click on the links below to learn. Of course our physicians will always take the time to discuss treatment options, including clinical trials, to determine the right plan of action for you.

Bladder
Bladder
Trial No. Trial Name
BMS
CA209-274
A Phase 3 Randomized, Double-Blind, Multi-Center Study of Adjuvant Nivolumab Versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
Blood
Blood
Trial No. Trial Name
Alexion
ALXN1210-aHUS-311
Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome
Breast
Breast
Trial No. Trial Name
Cascadian
ONT-380-206
HER2CLIMB
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs. Placebo in Combination with Capectiabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Syndax
SNDX-275-0602
(TRIO-025)
A Randomized , Placebo-Controlled, Double-Blind, Multicenter Phase 2 Study of Atezolizumab with or without Entinostat in Patients with Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in Phase
Colorectal
Colorectal
There are currently no active trials, please check again soon.
Kidney
Kidney
There are currently no active trials, please check again soon.
Leukemia
Leukemia
Trial No. Trial Name
AML
ABBVIE
M15-656
A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naïve Subjects with Acute Myeloid Leukemia Who are Ineligible for Standard Induction Therapy
*Special Note - Patients Must be Able to Receive Treatment at Lutheran Hospital
Lung
Lung
Trial No. Trial Name
SCLC
AstraZeneca
D419QC00001
Caspian
A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease On Hold Pending Availablilty of Etopside
NSCLC
BMS
CA209-384
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240mg Every 2 Weeks vs Nivolumab 480mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3mg/kg or 240 mg Every 2 Weeks
Lymphoma
Lymphoma
Trial No. Trial Name
TG Therapeutics
UTX-TGR-205
A Phase 2b Randomized Study of Ublituximab + TGR-1202 +/- Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma
Multiple Myeloma
Multiple Myeloma
There are currently no active trials, please check again soon.
Ovarian
Ovarian
Trial No. Trial Name
AstraZeneca
D8488C00001
Concerto
A Single Arm, Open-Label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women with Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who Do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation
Pancreatic
Pancreatic
Trial No. Trial Name
ARMO
AM0010-301
ARTIST 1
A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that Have Progressed During or Following a First-Line Gemcitabine Containing Regimen
Halozyme
HALO-109-301
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluranan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Prostate
Prostate
Trial No. Trial Name
SCRI
GU115
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide with or without the P13 Kinase/MTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
Solid Tumors
Solid Tumors
Trial No. Trial Name
Medivation
3800-01
A Phase 1 Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients with Advanced Solid Tumors and Normal or Varying degrees of Renal impairment. *Only open to Group D Severe Renal Impairment
BMS
CA209-627
"Basket"
An Open-label Phase 2 Multi-Cohort Trial of Nivolumab in Advanced or Metastatic Malignancies.
Benign Heme
Benign Heme
There are currently no active trials, please check again soon.